Hims acquires Eucalyptus

Hims & Hers Health, Inc. has announced a definitive agreement to acquire Eucalyptus, an Australian digital health firm, for up to $1.15 billion. This acquisition underscores the San Francisco-based company's strategic effort to expand its global footprint, particularly amid its ongoing legal and regulatory challenges in the United States. By acquiring Eucalyptus, Hims & Hers seeks to diversify its risk and revenue streams by broadening its consumer base outside the U.S.

The terms of the deal include an upfront payment of $240 million in cash upon closing, with the remainder tied to performance-based earnouts extending through early 2029. With this acquisition, Hims & Hers will integrate Eucalyptus' consumer-oriented virtual clinics and brands into its operations, adding roughly 775,000 customers and extending its presence to Australia, the UK, Germany, Canada, and Japan. Eucalyptus' brands include Juniper, Pilot, and Kin, offering services in weight management, men’s health, and fertility care.

This move comes as Hims & Hers faces legal scrutiny over its practice of selling compounded versions of GLP-1 medications like Wegovy and Ozempic as more affordable options. These compounded drugs are not FDA-approved, raising safety concerns and resulting in a lawsuit filed by Novo Nordisk against the company. In this context, the acquisition represents a shift toward geographic diversification to mitigate the potential impact of U.S.-centric legal challenges. Michael Abrams of Numerof & Associates suggests that this expansion could help reduce reliance on the domestic market.

The acquisition offers synergies between Hims & Hers' existing direct-to-consumer health solutions and Eucalyptus' established markets in non-U.S. territories. Their combined product offerings span essential areas such as men's and women's health, dermatology, and weight management, providing opportunities for cross-promotional strategies and integrated service packages. According to Warren Templeton from Health2047, this international diversification could introduce new revenue streams and innovation pipelines for Hims & Hers, although potential regulatory risks similar to those in the U.S. may arise abroad.

Moving forward, the deal’s success will be measured not only by integrating new markets and clients but also by navigating the uncertain regulatory landscapes in these regions. The performance-based earnout model indicates both potential and uncertainty, particularly regarding Eucalyptus' contributions from GLP-1 products. As Hims & Hers advances with its acquisition strategy, it remains to be seen how it will adapt to international market dynamics while resolving its ongoing legal issues domestically.